# Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer

> **NCT06220214** · EARLY_PHASE1 · RECRUITING · sponsor: **Alison Stopeck** · enrollment: 30 (estimated)

## Conditions studied

- Breast Cancer
- Locally Advanced Breast Cancer
- Neoadjuvant Chemotherapy
- HER2-positive Breast Cancer
- Triple Negative Breast Cancer
- TNBC, Triple Negative Breast Cancer

## Interventions

- **DIAGNOSTIC_TEST:** CEDM
- **DIAGNOSTIC_TEST:** CEDBT
- **DRUG:** Omnipaque 350mgI/mL Solution for Injection

## Key facts

- **NCT ID:** NCT06220214
- **Lead sponsor:** Alison Stopeck
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-06
- **Primary completion:** 2026-07-31
- **Final completion:** 2026-08-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06220214

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06220214, "Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06220214. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*